Results 191 to 200 of about 6,458 (228)

Abciximab in rescue therapy of thromboembolic events during endovascular treatment of cerebral aneurysms: single center experience of 49 cases. [PDF]

Front Neurol
Lenhart L, Ladenhauf V, Rass V, Treichl SA, Beer R, Freyschlag CF, Gizewski ER, Grams AE.   +7 more
europepmc   +1 more source

A Study of the Impact of Additives on the Physicochemical Properties of Eptifibatide-Loaded Microspheres for Drug Delivery

Anand Kyatanwar, Bala Prabhakar
openalex   +1 more source

Safety of Eptifibatide in Addition to Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Fatemeh Baharvand, Z. Hasani, Sahar Jafari, Mohammad Ali Esfandiar, Arsalan Salari, Motahare Hatami, Hamed Vahidi, Niloufar Akbari Parsa, Mahboobeh Gholipour   +8 more
openalex   +1 more source

Successful pharmaco-mechanical treatment of a subtotally occluded venous bypass graft in a patient presenting with acute coronary syndrome: a case report and review of the current literature on the role of local thrombolysis. [PDF]

Front Cardiovasc Med
Renker M, Sossalla S, Schoefthaler C, Korosoglou G.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Complications and Management of Eptifibatide-Induced Thrombocytopenia

Annals of Pharmacotherapy, 2021
Background Eptifibatide is used in acute coronary syndromes to reversibly block platelet aggregation by inhibiting the platelet glycoprotein IIb/IIIa receptor. A serious adverse effect of eptifibatide is a profound drop in platelet count, termed eptifibatide-induced thrombocytopenia (EIT).
Eli D. Ehrenpreis, Eli D. Ehrenpreis, Faisal Masood, Adib Chaus, Anna Hertsberg, Saad Hashmi   +5 more
openaire   +4 more sources

Clinical Pharmacology of Eptifibatide

The American Journal of Cardiology, 1997
Activation of receptor function of platelet membrane glycoprotein (GP) IIb-IIIa leads to the binding of fibrinogen and is the final common pathway to platelet aggregation. Platelet aggregates provide the structural basis for coronary thrombosis, a major cause of ischemic heart disease.
David R. Phillips, Robert M. Scarborough
openaire   +3 more sources

Delayed-onset eptifibatide-induced thrombocytopenia

American Journal of Health-System Pharmacy, 2023
Abstract Purpose We present a unique case of delayed-onset, profound eptifibatide-induced thrombocytopenia that occurred 5 days after initiation of the drug. Summary Eptifibatide is a platelet glycoprotein IIb/IIIa receptor inhibitor ...
Travis, Huffman, Evan, Gleaves, Glee, Lenoir, Rahil, Rafeedheen   +3 more
openaire   +2 more sources

Eptifibatide-induced thrombocytopenia

Journal of Thrombosis and Thrombolysis, 2007
Glycoprotein (GP) IIb/IIIa inhibitors reduce major adverse coronary events in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). Unlike the other GPIIb/IIIa inhibitors, eptifibatide is rarely associated with thrombocytopenia with only a few cases reported in the medical literature. Here we report a case of a 34-
A.J. Conrad Smith, Marwan M. Refaat, Daniel Edmundowicz   +2 more
openaire   +3 more sources